FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Daniel Podzamczer

Research Profile

Disorders

Chemicals & Drugs

Living Beings

HIV-1

Procedures

Concepts & Ideas

Geographic Areas

Spain

Co-author Network

Publications

TOP 3
Francois Raffi; Hans-Jürgen Stellbrink; Carlo Torti; Steve Almond; Mark Bloch; Clare Brennan; W David Hardy; David Margolis; Sherene Min; Chloe Orkin; Daniel Podzamczer; Vadim Pokrovsky; Federico Pulido; Anita Rachlis
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
Anthony Mills; Daniel Podzamczer; Charles Craig; Gerd Fätkenheuer; Jayvant Heera; Manuel Leal; Lynn McFadyen; Donna Mildvan; Alex R Rinehart; Soe Than; Hernan Valdez; Srinivas R Valluri; Manoli Vourvahis; Simon Portsmouth
Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.
Arkaitz Imaz; Christian Manzardo; Miquel Pujol; Alex Soriano; Rosa Bartolomé; Nazaret Cobos-Trigueros; Jordi Curto; M Angeles Dominguez; Vicenç Falcó; Daniel Podzamczer
Community-associated methicillin-resistant Staphylococcus aureus infections in HIV-infected patients in Spain.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Daniel Podzamczer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Francois Raffi; Hans-Jürgen Stellbrink; Carlo Torti; Steve Almond; Mark Bloch; Clare Brennan; W David Hardy; David Margolis; Sherene Min; Chloe Orkin; Daniel Podzamczer; Vadim Pokrovsky; Federico Pulido; Anita Rachlis
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
Lancet 2013;381(9868):735-43.
2013: Anthony Mills; Daniel Podzamczer; Charles Craig; Gerd Fätkenheuer; Jayvant Heera; Manuel Leal; Lynn McFadyen; Donna Mildvan; Alex R Rinehart; Soe Than; Hernan Valdez; Srinivas R Valluri; Manoli Vourvahis; Simon Portsmouth
Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.
Journal of acquired immune deficiency syndromes (1999) 2013;62(2):164-70.
2013: Arkaitz Imaz; Christian Manzardo; Miquel Pujol; Alex Soriano; Rosa Bartolomé; Nazaret Cobos-Trigueros; Jordi Curto; M Angeles Dominguez; Vicenç Falcó; Daniel Podzamczer
Community-associated methicillin-resistant Staphylococcus aureus infections in HIV-infected patients in Spain.
The Journal of infection 2013;66(2):199-201.
2013: J M Tiraboschi; N Rozas; G Barrera-Castillo; Elena Ferrer; M Maso-Serra; Jordi Niubo; Daniel Podzamczer
Etravirine concentrations in seminal plasma in HIV-infected patients.
The Journal of antimicrobial chemotherapy 2013;68(1):184-7.
2013: Arkaitz Imaz; José Antonio Iribarren; María Larrousse; José López Aldeguer; Mar Masiá; Montserrat Olmo; José Antonio Oteo; Maria Peñaranda; Daniel Podzamczer; Joan Romeu; Concepción Vilallonga; Jordi Curto; Pere Domingo; Félix Gutiérrez
Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
Antiviral therapy 2013;18(1):125-30.
2012: Daniel Podzamczer; Joaquín Portilla; Esteban Ribera; Ignacio Santos; Ferrán Segura; Pompeyo E. Viciana; Antonio Antela; Jorge Carmena; Manuel Castaño; Jordi Curto; Pere Domingo; Vicente Estrada; Elena Ferrer; Josefa Galindo; Hernando Knobel; Esteban Martínez; Eugenia Negredo; Antonio Ocampo; Maria-Jesús Pérez-Elías
Switching to raltegravir in virologically suppressed in HIV-1-infected patients: a retrospective, multicenter, descriptive study.
Current HIV research 2012;10(8):673-8.
2012: Esteban Martínez; Xabier Moreno; Ignacio Perez; Judit Pich; Daniel Podzamczer; Antonio Antela; Juan Berenguer; Polyana M D'Albuquerque; Pere Domingo; José M Gatell; Felix Gutierrez; Josep M Llibre
Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir.
AIDS (London, England) 2012;26(18):2315-26.
2012: Maria Saumoy; Esteban Ribera; José Luis Sánchez-Quesada; Bonaventura Clotet; Adrian Curran; Jordi Curto; Josep Maria Gatell; Hernando Knobel; Josep Maria Llibre; Esteban Martínez; Margarita Masó; Jordi Ordoñez-Llanos; Daniel Podzamczer
LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy.
Atherosclerosis 2012;225(1):200-7.
2012: Josep M Llibre; Daniel Podzamczer
Effect of efavirenz versus nevirapine in antiretroviral-naive individuals in the HIV-CAUSAL Collaboration Cohort.
AIDS (London, England) 2012;26(16):2117-8.
2012: Arkaitz Imaz; Daniel Podzamczer
The role of rilpivirine in clinical practice: strengths and weaknesses of the new nonnucleoside reverse transcriptase inhibitor for HIV therapy.
AIDS reviews 2012;14(4):268-78.
2012: Joaquin Burgos; Manuel Crespo; Adria Curran; Pere Domingo; Vicenç Falcó; Arkaitz Imaz; M Gracia Mateo; Jordi Navarro; Daniel Podzamczer; Esteve Ribera; Eva Van den Eynde; Sara Villar; Albert Pahissa
Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients.
The Journal of antimicrobial chemotherapy 2012;67(10):2479-86.
2012: Daniel Podzamczer; T Puig; Esteban Ribera; I Santos; J M Tiraboschi; Concepción Villalonga; M A Cárdenes; S Echevarría; J A García-Henarejos; J L Gómez-Sirvent; J C Lopez Bernaldo de Quirós; Pilar Barrufet; E Casas; A Castro; J Curto; Lluís Force; M Leal; J Lopez-Aldeguer; Josep Mallolas; Santiago Moreno; J Sanz
Long-term benefits of nevirapine-containing regimens: multicenter study with 506 patients, followed-up a median of 9 years.
Current HIV research 2012;10(6):513-20.
2012: M Olmo; M Peñaranda; Carlos Alonso-Villaverde; J Curto; Pere Domingo; F Gutiérrez; María Larrousse; J Romeu; Maria Saumoy; A Vila; J A Oteo; Daniel Podzamczer
Impact of antiretroviral therapy interruption on plasma biomarkers of cardiovascular risk and lipids: 144-week final data from the STOPAR study.
HIV medicine 2012;13(8):488-98.
2012: Antonio Javier Blasco; Vicente Boix; Bonaventura Clotet; Pere Domingo; Josep M Gatell; Juan González-García; Hernando Knobel; Pablo Lázaro; Josep M Llibre; Juan Carlos López; Fernando Lozano; José M Miró; Daniel Podzamczer; Juan Miguel Santamaría; Montserrat Tuset; Laura Zamora; José Ramón Arribas
[Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012].
Enfermedades infecciosas y microbiología clínica 2012;30(6):283-93.
2012: Joaquin Burgos; Manuel Crespo; Adria Curran; Pere Domingo; Vicenç Falcó; Arkaitz Imaz; Maria Gracia Mateo; Daniel Podzamczer; Eva Van den Eynde; Sara Villar; Esteve Ribera
Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen.
The Journal of antimicrobial chemotherapy 2012;67(6):1453-8.
2012: J M Tiraboschi; A Vila; Jordi Niubo; S Perez-Pujol; Daniel Podzamczer
Etravirine concentrations in CSF in HIV-infected patients.
The Journal of antimicrobial chemotherapy 2012;67(6):1446-8.
2012: Adrian Curran; Luis del Rio; Pere Domingo; Jose Maria Gatell; María Larrousse; Montserrat Lonca; Esteban Martinez; Daniel Podzamczer; Joaquin Burgos; Manuel Crespo; Maria Saumoy; Esteban Ribera
Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy.
AIDS (London, England) 2012;26(4):475-81.
2012: Adria Curran; Vicenç Falco; Jose Maria Gatell; Arkaitz Imaz; Montserrat Lonca; Esteban Martinez; Maria Martinez; Daniel Podzamczer; Patricia Barragan; Manuel Crespo; Sergio Vidal-Sicart; Esteban Ribera
Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial.
Antiviral therapy 2012;17(4):711-8.
2012: Arkaitz Imaz; José A Iribarren; Maria Larrousse; José López Aldeguer; Mar Masiá; Jordi Niubó; Montserrat Olmo; José A Oteo; Maria Peñaranda; Daniel Podzamczer; Joan Romeu; Concepción Vilallonga; Jordi Curto; Pere Domingo; Félix Gutiérrez
Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy.
Antiviral therapy 2012;17(3):577-83.
2012: Oscar Murillo; Ana Petit; Pedro Anda; Marta Carrera; Horacio Gil; Daniel Mimbrera; Daniel Podzamczer
Fatal bacillary angiomatosis mimicking an infiltrative vascular tumour in the immune restoration phase of an HIV-infected patient.
Antiviral therapy 2012;17(2):405-7.
2011: Antonio Javier Blasco; Bonaventura Clotet; Pere Domingo; José Ramón Arribas; Juan González-García; Pablo Lázaro; Josep M Llibre; Juan Carlos López-Bernaldo; Fernando Lozano; Daniel Podzamczer; Juan Miguel Santamaría; Montserrat Tuset; Laura Zamora; Josep M Gatell
[Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy].
Enfermedades infecciosas y microbiología clínica 2011;29(10):721-30.
2011: Arkaitz Imaz; Josep M Llibre; Bonaventura Clotet; Esteban Ribera; Daniel Podzamczer
The role of inactive nucleoside/nucleotide reverse transcriptase inhibitors in salvage therapy for drug-resistant HIV-1 infection in the era of new classes and new generation antiretrovirals.
Journal of acquired immune deficiency syndromes (1999) 2011;58(2):e46-8.
2011: Elena Ferrer; Josep M Gatell; Esteban Martínez; Eugenia Negredo; Jordi Ordóñez; Esteban Ribera; Joaquim Rosales; Maria Saumoy; Luis del Rio; Jordi Curto; Pere Domingo; Daniel Podzamczer
Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults.
AIDS research and human retroviruses 2011;27(10):1061-5.
2011: Daniel Podzamczer; P Reiss; J K Rockstroh; J Andrade-Villanueva; V Cairns; B Clotet; L de Rossi; P Domingo; H J Gellermann; S Taylor; V Soriano
Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).
HIV medicine 2011;12(6):374-82.
2011: José R Santos; Sebastián Videla; Isabel Bravo; Pere Domingo; Elena Ferrer; Arkaitz Imaz; Josep M Llibre; Daniel Podzamczer; Esteban Ribera; Bonaventura Clotet
Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients.
AIDS research and human retroviruses 2011;27(7):713-7.
2011: Jing Yuan; Anna M Cammett; Manuel Distel; Sheng Guo; David W Haas; David Hall; Zimei Huang; Supriya Jayadev; Piroon Mootsikapun; Daniel Podzamczer; Kiat Ruxrungtham; Stephen Storfer
Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent.
AIDS (London, England) 2011;25(10):1271-80.
2011: Marylène Lejeune; José M Miró; Elisa De Lazzari; Felipe García; Xavier Claramonte; Esteban Martínez; Esteban Ribera; Julio Arrizabalaga; José R Arribas; Pere Domingo; Elena Ferrer; Montserrat Plana; María-Eugenia Valls; Daniel Podzamczer; Tomás Pumarola; Alain Jacquet; Josep Mallolas; José M Gatell; Teresa Gallart
Restoration of T cell responses to toxoplasma gondii after successful combined antiretroviral therapy in patients with AIDS with previous toxoplasmic encephalitis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2011;52(5):662-70.
2011: Mark Nelson; Hans-Jürgen Stellbrink; Daniel Podzamczer; Dénes Banhegyi; Brian Gazzard; Andrew Hill; Yvon van Delft; Johan Vingerhoets; Thomas Stark; Stephan Marks
A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population.
AIDS (London, England) 2011;25(3):335-40.
2011: Joseph Gathe; Andrzej Horban; Mark Nelson; Thuy Nguyen; Daniel Podzamczer; Jaime Andrade-Villanueva; Johannes Bogner; Pedro Cahn; Murray Drulak; Steven Santiago; David Spencer; Chan-Loi Yong; Wei Zhang; Anne-Marie Quinson
Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients.
Antiviral therapy 2011;16(5):759-69.
2011: Maria Saumoy; Patricia Barragán; Rosa Bonet; Adrian Curran; Josep Maria Gatell; Hernando Knobel; Montserrat Loncá; Esteban Martínez; Eugenia Negredo; Jordi Ordoñez-Llanos; Daniel Podzamczer; Esteban Ribera
Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
Antiviral therapy 2011;16(4):459-68.
2011: Vicente Soriano; Keikawus Arastéh; Horacio Migrone; Thomas Lutz; Milos Opravil; Jaime Andrade-Villanueva; Francisco Antunes; Giovanni Di Perri; Daniel Podzamczer; Steve Taylor; Pere Domingo; Holger Gellermann; Lothar de Rossi
Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.
Antiviral therapy 2011;16(3):339-48.
2011: M Santin; Susana Casas; Maria Saumoy; Ana Andreu; Raquel Moure; Fernando Alcaide; Elena Ferrer; Daniel Podzamczer
Detection of latent tuberculosis by the tuberculin skin test and a whole-blood interferon-γ release assay, and the development of active tuberculosis in HIV-seropositive persons.
Diagnostic microbiology and infectious disease 2011;69(1):59-65.
2010: Juan Manuel Tiraboschi; Jordi Curto; Jordi Niubo; Daniel Podzamczer
Maraviroc concentrations in seminal plasma in HIV-infected patients.
Journal of acquired immune deficiency syndromes (1999) 2010;55(5):e35-6.
2010: Juan Manuel Tiraboschi; Jordi Curto; Jordi Niubo; Daniel Podzamczer
Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients.
Journal of acquired immune deficiency syndromes (1999) 2010;55(5):606-9.
2010: Frank A Post; Graeme J Moyle; Hans Jürgen Stellbrink; Pere Domingo; Daniel Podzamczer; Martin Fisher; Anthony G Norden; Matthias Cavassini; Armin Rieger; Marie-Aude Khuong-Josses; Teresa Branco; Helen C Pearce; Naomi Givens; Cindy Vavro; Michael L Lim
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.
Journal of acquired immune deficiency syndromes (1999) 2010;55(1):49-57.
2010: Arkaitz Imaz; Miquel Pujol; Patricia Barragán; M Angeles Domínguez; Juan Manuel Tiraboschi; Daniel Podzamczer
Community associated methicillin-resistant Staphylococcus aureus in HIV-infected patients.
AIDS reviews 2010;12(3):153-63.
2010: José M Miró; Christian Manzardo; Judith Pich; Pere Domingo; Elena Ferrer; José R Arribas; Esteban Ribera; Julio Arrizabalaga; Montserrat Loncá; Anna Cruceta; Elisa de Lazzari; montserrat fuster; Daniel Podzamczer; Montserrat Plana; José M Gatell
Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial.
AIDS research and human retroviruses 2010;26(7):747-57.
2010: Patricia Barragán; Rogelio López-Velez; Montserrat Olmo; Daniel Podzamczer
Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient.
The American journal of tropical medicine and hygiene 2010;83(1):10-2.
2010: Eva Van den Eynde; Juan Manuel Tiraboschi; Cristina Tural; Ricard Solà; José Antonio Mira; Daniel Podzamczer; Antoni Jou; Nuria Cañete; Juan Antonio Pineda; Albert Pahissa; Manuel Crespo
Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patients.
AIDS (London, England) 2010;24(7):975-82.
2010: Esteban Martínez; María Larrousse; Daniel Podzamczer; Ignacio Pérez; Félix Gutiérrez; Montserrat Loncá; Patricia Barragán; Ramon Deulofeu; Roser Casamitjana; Josep Mallolas; Judit Pich; José M Gatell
Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.
AIDS (London, England) 2010;24(3):F1-9.
2009: José R Santos; Josep M Llibre; Elena Ferrer; Pere Domingo; Arkaitz Imaz; José Moltó; Raquel Martin-Iguacel; Carme Caum; Daniel Podzamczer; Bonaventura Clotet
Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression.
HIV clinical trials 2009;10(6):432-8.
2009: Beatriz Mothe; Iñaki Perez; Pere Domingo; Daniel Podzamczer; Esteban Ribera; Adrian Curran; Consuelo Viladés; Francesc Vidal; David Dalmau; Enric Pedrol; Eugenia Negredo; José Moltó; Roger Paredes; Núria Perez-Alvarez; Jose Maria Gatell; Bonaventura Clotet
HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain.
Current HIV research 2009;7(6):597-600.
2009: David M Moore; Ross Harris; Viviane Lima; Hogg Robert; Margaret May; Benita Yip; Amy Justice; Amanda Mocroft; Peter Reiss; Fiona Lampe; Geneviève Chêne; Dominique Costagliola; Luigia Elzi; Michael J Mugavero; Antonella d'Arminio Monforte; Caroline Sabin; Daniel Podzamczer; Gerd Fätkenheuer; Schlomo Staszewski; John Gill; Jonathan A C Sterne
Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression.
Journal of acquired immune deficiency syndromes (1999) 2009;52(3):357-63.
2009: Imma Grau; Carmen Ardanuy; Josefina Liñares; Daniel Podzamczer; M H Schulze; Roman Pallares
Trends in mortality and antibiotic resistance among HIV-infected patients with invasive pneumococcal disease.
HIV medicine 2009;10(8):488-95.
2009: Esteban Martínez; José A Arranz; Daniel Podzamczer; Montserrat Loncá; José Sanz; Patricia Barragán; Esteban Ribera; Hernando Knobel; Victor Roca; Félix Gutiérrez; José L Blanco; Josep Mallolas; Josep M Llibre; Bonaventura Clotet; David Dalmau; Ferran Segura; José R Arribas; Jaime Cosín; Pilar Barrufet; Esperanza Casas; Elena Ferrer; Adrià Curran; Alicia González; Judit Pich; Ana Cruceta; Joan A Arnaiz; José M Miró; José M Gatell
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
Journal of acquired immune deficiency syndromes (1999) 2009;51(3):290-7.
2009: Daniel Podzamczer; Elena Ferrer; Esteban Martínez; Luis Del Rio; Joaquín Rosales; Jordi Curto; Esteban Ribera; Pilar Barrufet; Josep M Llibre; Miquel Aranda
How much fat loss is needed for lipoatrophy to become clinically evident?
AIDS research and human retroviruses 2009;25(6):563-7.
2009: Josep Mallolas; Daniel Podzamczer; Ana Milinkovic; Pere Domingo; Bonaventura Clotet; Esteve Ribera; Félix Gutiérrez; Hernando Knobel; Jaime Cosin; Elena Ferrer; José Alberto Arranz; Victor Roca; Francesc Vidal; Javier Murillas; Judit Pich; Enric Pedrol; Josep M Llibre; David Dalmau; Isabel García; Miquel Aranda; Ana Cruceta; Esteban Martínez; José L Blanco; Elisa de Lazzari; José M Gatell
Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.
Journal of acquired immune deficiency syndromes (1999) 2009;51(1):29-36.
2009: Nuria Virgili; Cesar Fisac; Esteban Martínez; Esteban Ribera; Josep Maria Gatell; Daniel Podzamczer
Proinflammatory cytokine changes in clinically stable, virologically suppressed, HIV-infected patients switching from protease inhibitors to abacavir.
Journal of acquired immune deficiency syndromes (1999) 2009;50(5):552-3.
2009: Joseph Gathe; Barbara A da Silva; Daniel E Cohen; Mona R Loutfy; Daniel Podzamczer; Rafael Rubio; Sara Gibbs; Theresa Marsh; Christian Naylor; Linda Fredrick; Barry Bernstein
A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks.
Journal of acquired immune deficiency syndromes (1999) 2009;50(5):474-81.
2009: Daniel Podzamczer; Montserrat Olmo; Jose Sanz; Vicente Boix; Eugenia Negredo; Hernando Knobel; Pere Domingo; Juan A Pineda; Consuelo Vilades; Jose Hernandez Quero; Lluis Force; Juan Gonzalez Lahoz; Pepa Muñoz; Josep M Llibre; Ana Mariño; Enrique Ortega; David Dalmau; Josep M Gatell; Esperanza Antón; Julio Sola; María J Galindo; Enric Pedrol; Jesus Sanz; Javier Torre de Lima; Juan Flores
Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients.
Journal of acquired immune deficiency syndromes (1999) 2009;50(4):390-6.
2009: Federico Pulido; Ignacio Pérez-Valero; Rafael Delgado; Alberto Arranz; Juan Pasquau; Joaquín Portilla; Rafael Rubio; Juan González-García; Pilar Miralles; Maria J Pérez-Elías; Antonio Ocampo; Asunción Hernando; Vicente Estrada; Bonaventura Clotet; Daniel Podzamczer; José R Arribas
Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression.
Antiviral therapy 2009;14(2):195-201.
2008: Patricia Barragan; Daniel Podzamczer
Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment.
Expert opinion on pharmacotherapy 2008;9(13):2363-75.
2008: Vicenç Falcó; Montserrat Olmo; Sara Villar del Saz; Ana Guelar; José R Santos; Mar Gutiérrez; Daniel Colomer; Elisabet Deig; Gracia Mateo; Milagro Montero; Enric Pedrol; Daniel Podzamczer; Pere Domingo; Josep M Llibre
Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study.
Journal of acquired immune deficiency syndromes (1999) 2008;49(1):26-31.
2008: Elena Ferrer; Jose Maria Gatell; Pochita Sanchez; Pere Domingo; Teresa Puig; Jordi Niubo; Cristina Cortes; Sergio Veloso; Enric Pedrol; Agathe Leon; Mar Gutierrez; Daniel Podzamczer
Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study.
AIDS research and human retroviruses 2008;24(7):931-4.
2008: Angeles Jaén; Anna Esteve; Josep M Miró; Cristina Tural; Alexandra Montoliu; Elena Ferrer; Melcior Riera; Ferran Segura; Lluís Force; Omar Sued; Josep Vilaró; Isabel Garcia; Angels Masabeu; Jordi Altès; Bonaventura Coltet; Daniel Podzamczer; Javier Murillas; Gemma Navarro; José M Gatell; Jordi Casabona
Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain).
Journal of acquired immune deficiency syndromes (1999) 2008;47(2):212-20.
2008: M Santin; Mariona Mestre; E Shaw; M J Barbera; Aurora Casanova; Jordi Niubo; F Bolao; Daniel Podzamczer; Francesc Gudiol
Impact of hepatitis C virus coinfection on immune restoration during successful antiretroviral therapy in chronic human immunodeficiency virus type 1 disease.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2008;27(1):65-73.
2007: Elena Ferrer; Jordi Niubo; Manel Crespo; José M Gatell; Jose Sanz; Sergio Veloso; Josep M Llibre; Pilar Barrufet; Pochita Sanchez; Daniel Podzamczer
Genotypic resistance in HIV-infected naive patients receiving abacavir plus lamivudine and efavirenz.
Journal of acquired immune deficiency syndromes (1999) 2007;46(2):253-5.
2007: Daniel Podzamczer; Martin S King; Cheri E Klein; Charles Flexner; Christine Katlama; Diane V Havlir; Scott L Letendre; Joseph J Eron; Scott C Brun; Barry Bernstein
High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response.
HIV clinical trials 2007;8(4):193-204.
2007: Daniel Podzamczer; Elena Ferrer; Pochita Sanchez; José M Gatell; Manel Crespo; Cesar Fisac; Montserrat Lonca; Jose Sanz; Jordi Niubo; Sergio Veloso; Josep M Llibre; Pilar Barrufet; María A Ribas; Esperanza Merino; Esteban Ribera; Javier Martínez-Lacasa; Carlos Alonso; Miquel Aranda; Federico Pulido; Juan Berenguer; Antonio Delegido; José Pedreira; Ana Lérida; Rafael Rubio; Luis del Río
Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.
Journal of acquired immune deficiency syndromes (1999) 2007;44(2):139-47.
2007: Esteban Martínez; Juan C López-Bernaldo De Quirós; Celia Miralles; Daniel Podzamczer
Considerations on the increase in blood pressure among antiretroviral-naive patients starting HAART.
AIDS (London, England) 2007;21(3):384-6.
2007: Esteban Martínez; Juan A Arnaiz; Daniel Podzamczer; David Dalmau; Esteban Ribera; Pere Domingo; Hernando Knobel; María Leyes; Enric Pedrol; Lluís Force; Elisa De Lazzari; José M Gatell
Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients.
AIDS (London, England) 2007;21(3):367-9.
2007: Ana María Caro-Murillo; Jesús Castilla; Santiago Pérez-Hoyos; José M Miró; Daniel Podzamczer; Rafael Rubio; Melcior Riera; Pompeyo E. Viciana; José López Aldeguer; José A Iribarren; Ignacio de los Santos-Gil; Juan Luis Gómez Sirvent; Juan Berenguer; Félix Gutiérrez; Maria Saumoy; Ferran Segura; Vicente Soriano; Alejandro Peña; Federico Pulido; José Antonio Oteo; Manuel Leal; Jordi Casabona; Julia del Amo; Santiago Moreno
[Spanish cohort of naïve HIV-infected patients (CoRIS): rationale, organization and initial results].
Enfermedades infecciosas y microbiología clínica 2007;25(1):23-31.
2006: Patricia Barragan; Cesar Fisac; Daniel Podzamczer
Switching strategies to improve lipid profile and morphologic changes.
AIDS reviews 2006;8(4):191-203.
2006: Margaret A Johnson; Joseph C Gathe; Daniel Podzamczer; Jean-Michel Molina; Christian T Naylor; Yi-Lin Chiu; Martin S King; Thomas J Podsadecki; George J Hanna; Scott C Brun
A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen.
Journal of acquired immune deficiency syndromes (1999) 2006;43(2):153-60.
2006: Jose M Miro; Juan C Lopez; Daniel Podzamczer; Jose Peña; Juan C Alberdi; Esteban Martínez; Pere Domingo; Jaime Cosin; Xavier Claramonte; José R Arribas; Miguel Santín; Esteban Ribera
Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006;43(1):79-89.
2006: Montserrat Olmo; Daniel Podzamczer
A review of nelfinavir for the treatment of HIV infection.
Expert opinion on drug metabolism & toxicology 2006;2(2):285-300.
2006: Juan Berenguer; María Jesús Pérez-Elías; José M Bellón; Hernando Knobel; Pablo Rivas-González; José M Gatell; Máximo Miguélez; José Hernández Quero; Juan Flores; Vicente Soriano; Ignacio Santos; Daniel Podzamczer; Monserrat Sala; Manuel Camba; Salvador Resino
Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohort.
Journal of acquired immune deficiency syndromes (1999) 2006;41(2):154-9.
2005: Emilia Condes; Koldo Aguirrebengoa; David Dalmau; José Manuel Estrada; Lluís Force; Miguel Górgolas; Xavier Badia; Daniel Podzamczer
[Validation of a questionnaire to estimate satisfaction with antiretroviral treatment: CESTA questionnaire].
Enfermedades infecciosas y microbiología clínica 2005;23(10):586-92.
2005: Federico Pulido; Esteban Ribera; Santiago Moreno; A Muñoz; Daniel Podzamczer; M A del Pozo; Antonio Rivero; F Rodríguez; I Sanjoaquín; Ramón Teira; Pompeyo E. Viciana; Concepción Villalonga; Antonio Antela; J Carmena; J Ena; E Gonzalez; José María Kindelán; Josep Mallolas; M Márquez; E Martínez
Once-daily antiretroviral therapy: Spanish Consensus Statement.
The Journal of antimicrobial chemotherapy 2005;56(5):808-18.
2005: Imma Grau; Roman Pallares; Fe Tubau; Marco H Schulze; Ferran Llopis; Daniel Podzamczer; Josefina Liñares; Francesc Gudiol
Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.
Archives of internal medicine 2005;165(13):1533-40.
2005: Cesar Fisac; Emilio Fumero; Manel Crespo; Beatriz Roson; Elena Ferrer; Nuria Virgili; Esteban Ribera; José M Gatell; Daniel Podzamczer
Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine.
AIDS (London, England) 2005;19(9):917-25.
2005: Angeles Jaén; Jordi Casabona; Anna Esteve; José M Miró; Cristina Tural; Elena Ferrer; Melcior Riera; Ferran Segura; Lluís Force; Omar Sued; Josep Vilaró; Angels Masabeu; Isabel García; Esther Dorca; Jordi Altès; Gemma Navarro; Daniel Podzamczer; Concepción Villalonga; Bonaventura Clotet; José M Gatell
[Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project].
Medicina clínica 2005;124(14):525-31.
2005: Daniel Podzamczer; Elena Ferrer; José M Gatell; Jordi Niubo; David Dalmau; Agathe Leon; Hernando Knobel; Carolina Polo; Daniel Iniguez; Isaac Ruiz
Early virological failure with a combination of tenofovir, didanosine and efavirenz.
Antiviral therapy 2005;10(1):171-7.
2004: Xavier Badía; Daniel Podzamczer; Irene Moral; Montse Roset; Juan A Arnaiz; Montse Loncà; Arnaldo Casiró; Beatriz Rosón; José M Gatell
Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy.
Antiviral therapy 2004;9(6):979-85.
2004: Luz Martin-Carbonero; Ana Barrios; Pere Saballs; Guillem Sirera; Jesús Santos; Rosano Palacios; M Eulalio Valencia; Marta Alegre; Daniel Podzamczer; Juan González-Lahoz
Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma.
AIDS (London, England) 2004;18(12):1737-40.
2004: Elena Ferrer; Elena Santamariña; Pere Domingo; Emilio Fumero; Esteban Ribera; Hernando Knobel; Juan Carlos Lopez; Ana Barrios; Daniel Podzamczer
Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/microl or less.
AIDS (London, England) 2004;18(12):1727-9.
2004: Eduardo Fernandez-Cruz; Santiago Moreno; J Navarro; Bonaventura Clotet; Emilio Bouza; JAVIER CARBONE; Jose Peña; J Pérez Molina; Daniel Podzamczer; R Rubio; Imma Ocaña; Federico Pulido; Pompeyo E. Viciana; J A Maradona; R Blazquez; C Barros; C Quereda; C Rodriguez-Sainz; Juana Gil; M L Abad; L Díaz; C Cantó; M A Muñoz; E Ferrer; Antoni Jou; Guillem Sirera; M Díaz; F Lopez; José M Gatell; J Gonzalez-Lahoz
Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects.
Vaccine 2004;22(23-24):2966-73.
2004: Alfonso Casado; Xavier Badia; Ezequiel Consiglio; Elena Ferrer; Alicia González; Enric Pedrol; José M Gatell; C Azuaje; Josep M Llibre; Miquel Aranda; Pilar Barrufet; Javier Martínez-Lacasa; Daniel Podzamczer
Health-related quality of life in HIV-infected naive patients treated with nelfinavir or nevirapine associated with ZDV/3TC (the COMBINE-QoL substudy).
HIV clinical trials 2004;5(3):132-9.
2004: Montserrat Plana; Elena Ferrer; Catalina Martínez; Daniel Podzamczer; Felipe García; María J Maleno; Juan J Barceló; Ana García; Maria J Barberá; Montserrat Lacarcel; José M Miró; Teresa Gallart; José M Gatell
Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.
Antiviral therapy 2004;9(2):197-204.
2003: Emilio Fumero; Daniel Podzamczer
New patterns of HIV-1 resistance during HAART.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2003;9(11):1077-84.
2003: Cesar Fisac; Nuria Virgili; Elena Ferrer; Maria J Barbera; Emilio Fumero; Concepcio Vilarasau; Daniel Podzamczer
A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study.
The Journal of clinical endocrinology and metabolism 2003;88(11):5186-92.
2003: Esteban Martínez; Juan A Arnaiz; Daniel Podzamczer; David Dalmau; Esteban Ribera; Pere Domingo; Hernando Knobel; Melcior Riera; Enric Pedrol; Lluís Force; Josep M Llibre; Ferran Segura; Cristóbal Richart; Cristina Cortés; Manuel Javaloyas; Miquel Aranda; Anna Cruceta; Elisa De Lazzari; José M Gatell
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.
The New England journal of medicine 2003;349(11):1036-46.
2003: Juan A Arnaiz; Josep Mallolas; Daniel Podzamczer; Jan Gerstoft; Jens D Lundgren; Pedro Cahn; Gerd Fätkenheuer; Antonella d'Arminio Monforte; Arnaldo Casiró; Peter Reiss; David Burger; Michael Stek; José M Gatell
Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load.
AIDS (London, England) 2003;17(6):831-40.
2003: Elena Ferrer; Daniel Podzamczer; Mireia Arnedo; Emilio Fumero; Paula McKenna; Alex Rinehart; José L Pérez; María J Barberá; Tomás Pumarola; José M Gatell; Francesc Gudiol
Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine.
The Journal of infectious diseases 2003;187(4):687-90.
2002: Marina Núńez; Carmen de Mendoza; Luisa Valer; Esperanza Casas; Soledad López-Calvo; Angeles Castro; Beatriz Rosón; Daniel Podzamczer; Amalia Rubio; Juan Berenguer; Vincent Soriano
Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinations.
Medical science monitor : international medical journal of experimental and clinical research 2002;8(9):CR620-3.
2002: Juan Miguel Santamaría; Carlos Barros; Fernando Dronda; Pablo Labarga; Daniel Podzamczer; Rafael Rubio
[Initial antiretroviral treatment].
Enfermedades infecciosas y microbiología clínica 2002;20 Suppl 2():3-9.
2002: Daniel Podzamczer; Elena Ferrer; Ezequiel Consiglio; José M Gatell; Pepa Perez; José Luis Perez; Elena Luna; Alicia González; Enric Pedrol; Luisa Lozano; Imma Ocaña; Josep M Llibre; Arnaldo Casiró; Miquel Aranda; Pilar Barrufet; Javier Martínez-Lacasa; José M Miró; Xavier Badía; Alfonso Casado; Sergio Lupo; Pedro Cahn; Manel Maños; Jordi Estela
A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
Antiviral therapy 2002;7(2):81-90.
2002: Daniel Podzamczer; Pilar Miralles; María de La Calle Md; Carlos Zarco; Juan Berenguer; José López Aldeguer; Eulalia Valencia; Rafael Rubio; Josep-Maria Ribera
[Recommendations of GESIDA/Spanish National Plan of AIDS on diagnosis and treatment of Kaposi's sarcoma and cervical cancer in HIV-infected patients].
Medicina clínica 2002;118(20):788-95.
2001: Daniel Podzamczer; Emilio Fumero
The role of nevirapine in the treatment of HIV-1 disease.
Expert opinion on pharmacotherapy 2001;2(12):2065-78.
2001: Alfonso Casado; Ezequiel Consiglio; Daniel Podzamczer; Xavier Badia
Highly active antiretroviral treatment (HAART) and health-related quality of life in naive and pretreated HIV-infected patients.
HIV clinical trials 2001;2(6):477-83.
2001: Daniel Podzamczer; J Ramón Arribas; J Mallolas; J María Peña; Federico Pulido
[Treatment of opportunistic infections among adult and adolescent patients infected with the human immunodeficiency virus in the era of highly active anti-retroviral therapy].
Enfermedades infecciosas y microbiología clínica 2001;19(8):376-92.
2001: M Núñez; Pere Saballs; M E Valencia; Jesús Santos; E Ferrer; I Santos; A Berrocal; M J Galindo; Daniel Podzamczer; J Gonzlez-Lahoz
Response to liposomal doxorubicin and clinical outcome of HIV-1-infected patients with Kaposi's sarcoma receiving highly active antiretroviral therapy.
HIV clinical trials 2001;2(5):429-37.
2001: Santiago Moreno; Daniel Podzamczer; Rosa M Blázquez; José A Iribarren; E Ferrer; J Reparaz; Jose Peña; E Cabrero; L Usán
Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin.
AIDS (London, England) 2001;15(9):1185-7.
2001: J C Lopez Bernaldo de Quiros; Jose M Miro; Jose Peña; Daniel Podzamczer; Juan C Alberdi; Esteban Martínez; Jaime Cosin; Xavier Claramonte; J Gonzalez; Pere Domingo; J L Casado; Esteban Ribera
A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
The New England journal of medicine 2001;344(3):159-67.
2000: Xavier Badia; Daniel Podzamczer; A Casado; C López-Lavid; M García
Evaluating changes in health status in HIV-infected patients: Medical Outcomes Study-HIV and Multidimensional Quality of Life-HIV quality of life questionnaires. Spanish MOS-HIV and MQOL-HIV Validation Group.
AIDS (London, England) 2000;14(10):1439-47.
2000: Daniel Podzamczer; Ezequiel Consiglio; Elena Ferrer; Francesc Gudiol
Efavirenz associated with corticosteroids in patients with previous severe hypersensitivity reaction due to nevirapine.
AIDS (London, England) 2000;14(3):331-2.
2000: Daniel Podzamczer; José M Miró; Elena Ferrer; José M Gatell; José-María Ramón; Esteban Ribera; Guillem Sirera; Anna Cruceta; Hernando Knobel; Pere Domingo; Rosa Polo; María Leyes; Jaime Cosin; M Carmen Fariñas; Julio Arrizabalaga; Javier Martínez-Lacasa; Francesc Gudiol
Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Spanish Toxoplasmosis Study Group.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2000;19(2):89-95.
1999: Felipe García; Joan Romeu; Imma Grau; Maria Antonia Sambeat; David Dalmau; Hernando Knobel; JL Gomez-Sirvent; Julio Arrizabalaga; Anna Cruceta; Bonaventura Clotet; Daniel Podzamczer; Tomás Pumarola; Teresa Gallart; WA O'Brien; José M Miró; José M Gatell
A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
AIDS (London, England) 1999;13(17):2377-88.
1999: Xavier Badia; Daniel Podzamczer; M Garcia; C López-Lavid C; Ezequiel Consiglio
A randomized study comparing instruments for measuring health-related quality of life in HIV-infected patients. Spanish MOS-HIV and MQOL-HIV Validation Group. Medical Outcomes Study HIV Health Survey.
AIDS (London, England) 1999;13(13):1727-35.
1999: Xavier Badia; L Guerra; M García; Daniel Podzamczer
[Evaluation of the quality of life in patients with HIV and AIDS infection].
Medicina clínica 1999;112(19):739-44.
1999: Xavier Badía; Daniel Podzamczer; C López-Lavid; M García
[Evidence-based medicine and the validation of quality-of-life questionnaires: the Spanish version of the MOS-HIV questionnaire for the evaluation of the quality of life in patients infected by HIV].
Enfermedades infecciosas y microbiología clínica 1999;17 Suppl 2():103-13.
1999: Elena Ferrer; Ezequiel Consiglio; Daniel Podzamczer; Imma Grau; José María Ramon; J L Perez; Francesc Gudiol
Analysis of the discontinuation of protease inhibitor therapy in routine clinical practice.
Scandinavian journal of infectious diseases 1999;31(5):495-9.
1998: Santiago Moreno; Julio Arrizabalaga; José M Gatell; Bonaventura Clotet; Koldo Aguirrebengoa; Antonio Antela; José A Iribarren; Fernando Laguna; José M Miró; Imma Ocaña; R Rubio; Pompeyo E. Viciana; Daniel Podzamczer
[Recommendations for antiretroviral treatment in 1998. AIDS Working Group of the Spanish Society for Infectious Diseases and Clinical Microbiology (SEIMC)].
Enfermedades infecciosas y microbiología clínica 1998;16(8):374-6.
1998: S Moreno; Javier Ariza; F J Espinosa; Daniel Podzamczer; J M Miró; Antonio Rivero; M Rodríguez-Zapata; Julio Arrizabalaga; R Mateos; F Herrero
Brucellosis in patients infected with the human immunodeficiency virus.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1998;17(5):319-26.
1998: S Moreno; Julio Arrizabalaga; José M Gatell; Bonaventura Clotet; Koldo Aguirrebengoa; A Antela; José A Iribarren; Fernando Laguna; José M Miró; Imma Ocaña; R Rubio; Pompeyo E. Viciana; Daniel Podzamczer
[Recommendations on antiretroviral treatment. The AIDS Study Group of the Spanish Society of Infectious Diseases and Clinical Microbiology].
Medicina clínica 1998;110(3):109-16.
1997: Nuria Virgili; Mireia Farriol; JM Castellanos; M Giró; Daniel Podzamczer; P A M
Evaluation of immune markers in asymptomatic AIDS patients receiving fish oil supplementation.
Clinical nutrition (Edinburgh, Scotland) 1997;16(5):257-61.
1997: Daniel Podzamczer; Elena Ferrer; A García; José-María Ramón; J Niubó; Miguel Santín; G Rufí; J L Pérez; R Martín; Francesc Gudiol
pp65 antigenemia as a marker of future CMV disease and mortality in HIV-infected patients.
Scandinavian journal of infectious diseases 1997;29(3):223-7.
1996: Antonio Antela; Daniel Podzamczer; I Ruiz; F Parras
[Anti-retroviral treatment. Approach to previously treated patients].
Enfermedades infecciosas y microbiología clínica 1996;14 Suppl 1():24-30.
1996: José M Gatell; Juan González-Lahoz; B Clotet; F Antunes; L Kasparova; A Gil-Aguado; P Saballs; J M Santamaria; Daniel Podzamczer; J M Miro; A Jou; J Verdejo; Manuela Doroana; J Thomis
Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1996;12(3):249-58.
1995: A Martos; Daniel Podzamczer; J Martinez-Lacasa; G Rufi; M Santin; Francesc Gudiol
Steroids do not enhance the risk of developing tuberculosis or other AIDS-related diseases in HIV-infected patients treated for Pneumocystis carinii pneumonia.
AIDS (London, England) 1995;9(9):1037-41.
1995: Daniel Podzamczer; José M Miró; F Bolao; José M Gatell; J Cosín; G Sirera; P Domingo; F Laguna; J Santamaría; J Verdejo
Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS. Spanish Toxoplasmosis Study Group.
Annals of internal medicine 1995;123(3):175-80.
1995: Daniel Podzamczer; A Salazar; J Jiménez; Ezequiel Consiglio; Miguel Santín; A Casanova; G Rufí; Francesc Gudiol
Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV.
Annals of internal medicine 1995;122(10):755-61.
1995: Miguel Santín; Daniel Podzamczer; I Ricart; J Mascaró; J M Ramón; A Dominguez; G Rufí; Francesc Gudiol
Utility of the gallium-67 citrate scan for the early diagnosis of tuberculosis in patients infected with the human immunodeficiency virus.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1995;20(3):652-6.
1995: A Salazar; Daniel Podzamczer; R Reñe; M Santin; J L Perez; Isidro Ferrer; P Fernandez-Viladrich; Francesc Gudiol
Cytomegalovirus ventriculoencephalitis in AIDS patients.
Scandinavian journal of infectious diseases 1995;27(2):165-9.
1994: C Ferré; J Mascaró; C Benasco; E Ramos; J L Pérez; Daniel Podzamczer
[Acute abdomen due to cytomegalovirus in AIDS patients. Apropos 2 cases].
Medicina clínica 1994;103(6):219-21.
1994: F Bolao; Daniel Podzamczer; M Ventin; Francesc Gudiol
Efficacy of acute phase and maintenance therapy with itraconazole in an AIDS patient with sporotrichosis.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1994;13(7):609-12.
1994: Daniel Podzamczer
[Treatment and primary and secondary prevention of cerebral toxoplasmosis in patients with HIV infection].
Enfermedades infecciosas y microbiología clínica 1994;12(3):158-63.
1994: C Ferré; F Báguena; Daniel Podzamczer; C Sánchez; Pedro F Viladrich; Javier Garau; Francesc Gudiol
Lung cavitation associated with Pneumocystis carinii infection in the acquired immunodeficiency syndrome: a report of six cases and review of the literature.
The European respiratory journal 1994;7(1):134-9.
1993: Ana Guelar; José M Gatell; J Verdejo; Daniel Podzamczer; L Lozano; E Aznar; José M Miró; Josep Mallolas; L Zamora; J González
A prospective study of the risk of tuberculosis among HIV-infected patients.
AIDS (London, England) 1993;7(10):1345-9.
1993: Daniel Podzamczer; Miguel Santín; J Jimenez; A Casanova; F Bolao; G R Gudiol
Thrice-weekly cotrimoxazole is better than weekly dapsone-pyrimethamine for the primary prevention of Pneumocystis carinii pneumonia in HIV-infected patients.
AIDS (London, England) 1993;7(4):501-6.
1993: Daniel Podzamczer; F Bolao; B Clotet; P García; A Casanova; X Pagerols; Francesc Gudiol
Low-dose interferon alpha combined with zidovudine in patients with AIDS-associated Kaposi's sarcoma.
Journal of internal medicine 1993;233(3):247-53.
1993: J T Martínez Lacasa; Daniel Podzamczer; G Rufí; F Bolao; J L Pérez; Francesc Gudiol
[Cytomegalovirus disease in patients with acquired immunodeficiency syndrome. Report of 63 cases].
Medicina clínica 1993;100(2):41-5.
1993: Daniel Podzamczer; A Martos; I Ferrer; M Santin; Francesc Gudiol
Hepatic and pulmonary pneumocystosis during primary prophylaxis for Pneumocystis carinii pneumonia with dapsone/pyrimethamine.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1993;16(1):171.
1992: A Martos; J Mascaró; Miguel Santín; Javier Ariza; Jordi Carratalà; Daniel Podzamczer
[Pulmonary cryptococcosis in AIDS].
Enfermedades infecciosas y microbiología clínica 1992;10(10):607-10.
1992: A Martos; M A Domínguez; J Martínez Lacasa; Daniel Podzamczer
[Granulocyte and macrophage colony stimulating factor (GM-CSF) in patients with acquired immunodeficiency syndrome and neutropenia].
Medicina clínica 1992;99(5):196-7.
1992: R Reñé; J Mascaró; J L Pérez; F Bolao; J A Martínez-Matos; Daniel Podzamczer
[Lumbosacral polyradiculomyelitis caused by cytomegalovirus in a patient with acquired immunodeficiency syndrome].
Medicina clínica 1992;98(13):499-501.
1991: J T Martínez Lacasa; J Burillo; R Niubó; G Rufí; Daniel Podzamczer; A Mariscal; R Reñé; F Fernández Nogués
[Cerebral tuberculoma. Report of 8 cases].
Medicina clínica 1991;97(6):218-23.
1990: Daniel Podzamczer; I Ricart; F Bolao; Vicens Romagosa; D Bonnin; N Guionnet; Francesc Gudiol
Gallium-67 scan for distinguishing follicular hyperplasia from other AIDS-associated diseases in lymph nodes.
AIDS (London, England) 1990;4(7):683-5.
1990: F Bolao; Daniel Podzamczer; Francesc Gudiol
[Toxoplasmosis in patients with HIV infections: diagnosis and treatment].
Enfermedades infecciosas y microbiología clínica 1990;8(6):376-83.
1990: Miguel Santín; Daniel Podzamczer; F Bolao; J Prat; G Rufí; Javier Ariza; J Lillo
[Ocular toxoplasmosis in patients with acquired immunodeficiency syndrome].
Medicina clínica 1990;94(11):423-5.
1990: Daniel Podzamczer; F Bolao; Francesc Gudiol
Oral hairy leukoplakia and zidovudine therapy.
Archives of internal medicine 1990;150(3):689.
1990: Daniel Podzamczer; Francesc Gudiol; F Bolao; José M Gatell; B Clotet; José M Miró
[Treatment of the most common infections in patients with human immunodeficiency virus infection. Task-force on AIDS of the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica].
Enfermedades infecciosas y microbiología clínica 1990;8(3):161-75.
1989: José M Gatell; Daniel Podzamczer; B Clotet; C Estany; J M Miro
Natural history of HIV infection in European drug users.
AIDS (London, England) 1989;3(6):404.
1989: Daniel Podzamczer; F Bolao; X Pagerols; M Pasarín; I Ferrer; A Romeu; Francesc Gudiol; F Fernández-Nogués
[Hairy leukoplakia: a new disease of the oral mucosa associated with infection by the human immunodeficiency virus].
Medicina clínica 1989;92(13):488-91.
1988: J M Gatell; Daniel Podzamczer; B Clotet; I Ocaña; C Estany; M Figuerola; D Mariscal
[Incidence of infection with human immunodeficiency virus and acquired immunodeficiency syndrome in a population from the Barcelona area].
Medicina clínica 1988;91(18):681-4.
1985: Daniel Podzamczer; E Buendía; M Mestre; L Urbiztondo; J Comellas; Francesc Gudiol
[Changes in lymphocyte subpopulations in hospitalized drug addicts].
Medicina clínica 1985;85(9):360-3.
1985: Daniel Podzamczer; Antonio Vidaller; S Sancho; M T González; J Comellas; F Fernández Nogués
[Use of the potassium permanganate technique in the differential diagnosis of amyloidoses].
Medicina clínica 1985;84(8):305-7.